NasdaqGM:ADMABiotechs
ADMA Biologics (ADMA) Could Be 52% Undervalued After Class Action Lawsuits
ADMA Biologics (ADMA) is under pressure after multiple securities class action lawsuits alleged undisclosed related party transactions, channel stuffing of ASCENIV inventory, and weak internal controls, following critical investigative reports and sharp stock price declines.
See our latest analysis for ADMA Biologics.
Recent lawsuits and investigative reports have followed a prolonged weak patch for ADMA Biologics, with the share price down 52.6% year to date and the 1 year total shareholder...